Health Economics›Low-grade glioma›Recurrent or progressive, non-curative therapy

Recurrent or progressive, non-curative therapy

Low-grade glioma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Dabrafenib and Trametinib Variant #01	—	R 52 791	28d	~10.7 mo	—	~2	~R 105 582 PFS proxy · indirect	6
Cisplatin and Etoposide (EP) Variant #22	—	R 1 819	21d	~5.0 mo	~10.2 mo	~4	~R 7 277 PFS proxy · indirect	13

2 of 2 regimens shown